Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent gastric cancer to be refractory to chemotherapy by using new tumor antigen URLC10 and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularization

Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent gastric cancer to be refractory to chemotherapy by using new tumor antigen URLC10 and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularization - Phase I / II clinical trial of peptide vaccination therapy for gastric cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002409

Enrollment

Registered

2009-08-31

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Cancer vaccination therapy by using new tumor antigen URLC10 and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularization against patients who have unresectable / r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have unresectable / recurrent gastric cancer to be refractory to chemotherapy 2. Performance status (ECOG) of the patients are 0-2. 3. more than 20, less than 85 years of age. 4. The presence or absence of measurable or evaluable lesions by RECIST was not taken into account. 5. Patients who have undergone operation, and recovered the influence by surgery. Or two weeks or more have passed since pre-medical treatment. 6. Patients who can expect the survival of three months or more. 7. WBC count more than 3000/mm3, less than 15000/mm3. Plt count more than 75000/mm3. AST and ALT less than 150IU/L. T-Bil less than 3.0mg/dl. Creatinine less than 2.0mg/dl. 8. All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation. 2. Patients have uncontrollable severe infectious diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunosuppression agent during clinical trial. 5. Patients have uncontrollable double cancer. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
immunological response and clinocal efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026